Dexcom Smart Basal, the first and only continuous glucose monitor (CGM)–integrated basal insulin dosing optimizer, has received FDA clearance.
It is designed for adults with type 2 diabetes (T2D) on glargine U-100 long-acting insulin therapy.
Dexcom Smart Basal uses data from the Dexcom G7 15-day sensor and logged insulin doses to generate personalized daily recommendations that help users optimize their long-acting insulin dose under their health care provider's guidance.
With an overall mean absolute relative difference of 8%, the Dexcom G7 15-day enhances the performance of Dexcom CGM systems, which are clinically proven to lower hemoglobin A1C, reduce both high- and low-glucose episodes, and improve time in range.
【MORE】